PURPOSE: The European Bone Marrow Transplantation (EBMT) Solid Tumor Registry (STR) contains detailed information on children with advanced neuroblastoma who, after standard-dose induction chemotherapy and surgery, received myeloablative megatherapy (MGT) followed by stem-cell transplantation (SCT). This data base was analyzed to identify factors that predict event-free survival (EFS).PATIENTS AND METHODS: Eligibility criteria were stage IV neuroblastoma, age over 1 year at diagnosis, and no relapse before MGT/SCT. Between February 1978 and July 1992, 549 patients were registered by 36 European transplant centers. The median age at diagnosis was 36 months (range, 13 to 216 months) and the male-female ratio was 1:45. Before MGT, 157 patients were in complete remission (CR), 156 in very good partial remission (VGPR), and 208 in partial remission (PR), whereas 24 had had only a minor response (MR). One hundred ten of 546 patients had undergone two successive MGT procedures. The median observation time was 60 months (range, 12 to 187 months).RESULTS: Actuarial EFS is 26% at 5 years. Multivariate analysis by the Cox proportional hazards regression model included 529 patients with complete data sets. After adjustment for treatment duration before MGT and double MGT procedures, two adverse, independent risk factors that influenced EFS were identified: (1) persisting skeletal lesions before MGT as defined by technetium (99TC) scans and/or meta-iodobenzylguanidine (mIBG) scans (P = .004) and (2) persisting bone marrow involvement before MGT (P = .03).CONCLUSION: After induction treatment, persisting skeletal disease as defined above and persisting bone marrow involvement may be predictive of a particularly poor outcome. Physicians may consider this an additional important tool to decide the patient's management

MULTIVARIATE ANALYSIS OF RISK FACTORS IN STAGE IV NEUROBLASTOMA PATIENTS OVER THE AGE OF ONE YEAR TREATED WITH MEGATHERAPY AND STEM CELL TRANSPLANTATION: A REPORT FROM THE EUROPEAN BONE MARROW TRANSPLANTATION SOLID TUMOR REGISTRY / LADENSTEIN, R.; PHILIP, T.; LASSET, C.; HARTMAN, O.; GARAVENTA, A.; PINKERTON, R.; MICHON, J.; PRITCHARD, J.; KLINGEBIEL, T.; KREMENS, B.; PEARSON, A.; PAOLUCCI, Paolo. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 16:(1998), pp. 953-965.

MULTIVARIATE ANALYSIS OF RISK FACTORS IN STAGE IV NEUROBLASTOMA PATIENTS OVER THE AGE OF ONE YEAR TREATED WITH MEGATHERAPY AND STEM CELL TRANSPLANTATION: A REPORT FROM THE EUROPEAN BONE MARROW TRANSPLANTATION SOLID TUMOR REGISTRY.

PAOLUCCI, Paolo
1998

Abstract

PURPOSE: The European Bone Marrow Transplantation (EBMT) Solid Tumor Registry (STR) contains detailed information on children with advanced neuroblastoma who, after standard-dose induction chemotherapy and surgery, received myeloablative megatherapy (MGT) followed by stem-cell transplantation (SCT). This data base was analyzed to identify factors that predict event-free survival (EFS).PATIENTS AND METHODS: Eligibility criteria were stage IV neuroblastoma, age over 1 year at diagnosis, and no relapse before MGT/SCT. Between February 1978 and July 1992, 549 patients were registered by 36 European transplant centers. The median age at diagnosis was 36 months (range, 13 to 216 months) and the male-female ratio was 1:45. Before MGT, 157 patients were in complete remission (CR), 156 in very good partial remission (VGPR), and 208 in partial remission (PR), whereas 24 had had only a minor response (MR). One hundred ten of 546 patients had undergone two successive MGT procedures. The median observation time was 60 months (range, 12 to 187 months).RESULTS: Actuarial EFS is 26% at 5 years. Multivariate analysis by the Cox proportional hazards regression model included 529 patients with complete data sets. After adjustment for treatment duration before MGT and double MGT procedures, two adverse, independent risk factors that influenced EFS were identified: (1) persisting skeletal lesions before MGT as defined by technetium (99TC) scans and/or meta-iodobenzylguanidine (mIBG) scans (P = .004) and (2) persisting bone marrow involvement before MGT (P = .03).CONCLUSION: After induction treatment, persisting skeletal disease as defined above and persisting bone marrow involvement may be predictive of a particularly poor outcome. Physicians may consider this an additional important tool to decide the patient's management
16
953
965
MULTIVARIATE ANALYSIS OF RISK FACTORS IN STAGE IV NEUROBLASTOMA PATIENTS OVER THE AGE OF ONE YEAR TREATED WITH MEGATHERAPY AND STEM CELL TRANSPLANTATION: A REPORT FROM THE EUROPEAN BONE MARROW TRANSPLANTATION SOLID TUMOR REGISTRY / LADENSTEIN, R.; PHILIP, T.; LASSET, C.; HARTMAN, O.; GARAVENTA, A.; PINKERTON, R.; MICHON, J.; PRITCHARD, J.; KLINGEBIEL, T.; KREMENS, B.; PEARSON, A.; PAOLUCCI, Paolo. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 16:(1998), pp. 953-965.
Ladenstein, R.; Philip, T.; Lasset, C.; Hartman, O.; Garaventa, A.; Pinkerton, R.; Michon, J.; Pritchard, J.; Klingebiel, T.; Kremens, B.; Pearson, A.; Paolucci, Paolo
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/456417
Citazioni
  • ???jsp.display-item.citation.pmc??? 29
  • Scopus 157
  • ???jsp.display-item.citation.isi??? 134
social impact